Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EVE-Treg

Phase 1Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Graft Versus Host Disease (cgvhd)Recruiting

Graft Versus Host Disease (cgvhd)Phase 1

Recruiting

Timeline

Expected Milestones

Q2 2031

Phase 1Recruiting

Graft Versus Host Disease (cgvhd)

NCT06991361

Clinical

Trials by Indication[1]

Graft Versus Host Disease (cGvHD)1 trial

A Phase I Trial of Ex Vivo-Expanded (EVE) Regulatory T Cells in Combination With Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Recruiting·LLeslie Kean·Phase 1·NCT06991361·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EVE-Treg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EVE-Treg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EVE-Treg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leslie Kean company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: LLeslie Kean

Related News